

NOTICE

END OF ALTERNATIVE MEDICATION AUTHORIZATION

An Act respecting prescription drug insurance (chapter A-29.01, s. 60.1)

The following medication:

99101409	<i>Oxybutynine chloride</i>		1	5 mg	Caps.		
----------	-----------------------------	--	---	------	-------	--	--

is no longer authorized an alternative for the following medications, which are once again available:

02163543	<i>Apo-Oxybutynin</i>	Apotex	100 500	5 mg	Tab.	9.86 49.30	0.0986 0.0986
02230394	<i>Novo-Oxybutynin</i>	Novopharm	100 500	5 mg	Tab.	9.86 49.30	0.0986 0.0986
02350238	<i>Oxybutynin</i>	Sanis	100 500	5 mg	Tab.	9.86 49.30	0.0986 0.0986
02220636	<i>Oxybutynine-5</i>	Pro Doc	100 500	5 mg	Tab.	9.86 49.30	0.0986 0.0986
02240550	<i>pms-Oxybutynin</i>	Phmscience	100 500	5 mg	Tab.	9.86 49.30	0.0986 0.0986
02299364	<i>Riva-Oxybutynin</i>	Riva	100 500	5 mg	Tab.	9.86 49.30	0.0986 0.0986

This notice has effect from 15 June 2018.

Québec, 28 May 2018

Original signed by :

PAUL MARCEAU
President and Chief Executive Officer
Régie de l'assurance maladie du Québec

Publication of this notice on the website of the Régie de l'assurance maladie du Québec imparts authentic value to it.